Background: Atrial fibrillation (AF) is a common clinical arrhythmia. Tongmai Yangxin Pill (TMYX) is a traditional Chinese medicine prescription for treating arrhythmia, but the mechanism of action in AF remains unclear. Therefore, this study aimed to explore the mechanism of TMYX in AF and provide a new treatment target.
Methods: The effective components of TMYXwere screened in onlinedatabase. Differentially expressed genes (DEGs) between AF and control samples were obtained via differential expression analysis. Candidate genes were obtained by overlapping DEGs and independent drug targets obtained by screening. Subsequently, these candidate genes were included in Mendelian randomization (MR) analysis to obtain candidate key genes. Through machine learning algorithms, candidate key genes were further screened to obtain biomarkers. Furthermore, immune infiltration analysis and molecular docking were implemented.
Results: By intersecting 2,845 DEGs and 1,099 independent drug targets, 174 candidate genes were obtained. A sum of 14 candidate key genes were identified to be causally related to AF. Notably, KMO, SERPINE1, CYP17A1 and HSD17B1 were identified as biomarkers. We found regulatory T cell showed a significant positive correlation with four biomarkers. Through a series of screening, a drugs-compounds-biomarkers network containing 4 biomarkers, 8 drugs, and 26 compounds was constructed. In this network, Ophiopogonis Radix targeted CYP17A1, HSD17B1 and SERPINE1 simultaneously through different compounds. The molecular docking binding energy between these compounds and biomarkers was stable, such as SERPINE1and quercetin.
Conclusion: In this study, four biomarkers were identified, which provided a new treatment target for AF.